Developing Life‑Saving Plasma‑Derived Medicinal Product

SK plasma core Indonesia is a biopharmaceutical company dedicated to the development of plasma‑derived medicinal products (PDMPs), which are essential medicines used to treat life‑threatening and rare medical conditions where treatment options are limited or unavailable.

As part of SK plasma’s global plasma business, SK plasma core Indonesia applies advanced plasma fractionation expertise, strict quality standards, and GMP‑based operations to the Indonesian healthcare environment. The company is committed to producing safe, high‑quality medicines that directly protect human life, while building a professional biopharmaceutical organization grounded in responsibility, precision, and long‑term sustainability.

Building Indonesia’s First Plasma Fractionation Capability

SK plasma core Indonesia is leading the development of Indonesia’s first plasma fractionation facility, establishing a core healthcare capability that has never existed in the country before.

Until now, plasma‑derived products have depended entirely on imports, limiting supply stability and local control over essential treatments.

By enabling plasma donated by Indonesians to be processed locally into life‑saving medicines, SK plasma core Indonesia is establishing a new national capability that has never existed before. This initiative goes beyond building a manufacturing plant, it represents a long‑term commitment to technology transfer, workforce development, and the creation of a sustainable plasma‑based healthcare ecosystem.